EUVIMEDEUVIMED entdecken
Multizentrische Studie

SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases

María-Carmen Rubio Rodríguez, Xin Chen-Zhao, Ovidio Hernando, Sonia Flamarique, Pedro Fernández-Letón, Maider Campo, Mercedes López, Maitane Rodríguez, Daniel Zucca, Daniel Martínez, Emilio Sánchez-Saugar, Fernando Mañeru und 13 weitere

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03403-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von María-Carmen Rubio Rodríguez und 24 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain. crubio@hmhospitales.com. Hauptthemen laut MEDLINE: Radiosurgery, Liver Neoplasms, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aimed to assess the efficacy and tolerability of stereotactic body radiation therapy (SBRT) for the treatment of liver metastases. METHODS: Patients with up to 5 liver metastases were enrolled in this prospective multicenter study and underwent SBRT. Efficacy outcomes included in-field local control (LC), progression-free survival (PFS), and overall survival (OS). Acute and late toxicities were evaluated using CTCAE v.4.0. RESULTS: A total of 52 patients with 105 liver metastases were treated between 2015 and 2018. The most common primary tumor was colorectal cancer (72% of cases). Liver metastases were synchronous with the primary tumor diagnosis in 24 patients (46.2%), and 21 patients (40.4%) presented with other extrahepatic oligometastases. All patients underwent intensity-modulated radiation therapy (IMRT)/volumetric-modulated arc therapy (VMAT) with image-guided radiation therapy (IGRT) and respiratory gating, and a minimum biologically effective dose (BED10Gy) of 100 Gy was delivered to all lesions. With a median follow-up of 23.1 months (range: 13.4-30.9 months) since liver SBRT, the median actuarial local progression-free survival (local-PFS) was not reached. The actuarial in-field LC rates were 84.9% and 78.4% at 24 and 48 months, respectively. The median actuarial liver-PFS and distant-PFS were 11 and 10.8 months, respectively. The actuarial median overall survival (OS) was 27.7 months from SBRT and 52.5 months from metastases diagnosis. Patients with lesion diameter ≤ 5 cm had significantly better median liver-PFS (p = 0.006) and OS (p = 0.018). No acute or late toxicities of grade ≥ 3 were observed. CONCLUSIONS: This prospective multicenter study confirms that liver SBRT is an effective alternative for the treatment of liver metastases, demonstrating high rates of local control and survival while maintaining a low toxicity profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryLiver NeoplasmsRadiotherapy, Intensity-ModulatedHumansMaleProspective StudiesFemaleMiddle AgedAgedAged, 80 and overAdultProgression-Free SurvivalColorectal NeoplasmsRadiotherapy, Image-GuidedSurvival Rate

Stichwörter der Autor:innen

Liver metastasesOligometastasesSBRT

Autor:innen und Institutionen

  • Radiation Oncology, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain. crubio@hmhospitales.com.
  • Radiation Oncology, Hospital Universitario HM Puerta del Sur, HM Hospitales, Madrid, Spain.
  • Radiation Oncology, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.
  • Radiation Oncology, Complejo Hospitalario de Navarra, Navarra, Spain.
  • Medical Physics, Hospital Universitario HM Sanchinarro, HM Hospitales, Madrid, Spain.
  • Medical Physics, Complejo Hospitalario de Navarra, Navarra, Spain.

Zitieren

APA

Rodríguez, M. R., Chen-Zhao, X., Hernando, O., Flamarique, S., Fernández-Letón, P., Campo, M., López, M., Rodríguez, M., Zucca, D., Martínez, D., Sánchez-Saugar, E., Mañeru, F., Ruiz-Zorrilla, J. G., de Acilu, P. G., Valero, J., Montero, A., Ciérvide, R., Alvarez, B., García-Aranda, M., …, & Arias, F. (2024). SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03403-w

Vancouver

Rodríguez MR, Chen-Zhao X, Hernando O, Flamarique S, Fernández-Letón P, Campo M, et al. SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03403-w

BibTeX
@article{Rodrguez2024,
  author = {Rodríguez, María-Carmen Rubio and Chen-Zhao, Xin and Hernando, Ovidio and Flamarique, Sonia and Fernández-Letón, Pedro and Campo, Maider and López, Mercedes and Rodríguez, Maitane and Zucca, Daniel and Martínez, Daniel and Sánchez-Saugar, Emilio and Mañeru, Fernando and Ruiz-Zorrilla, Juan García and de Acilu, Paz García and Valero, Jeannette and Montero, Angel and Ciérvide, Raquel and Alvarez, Beatriz and García-Aranda, Mariola and Alonso, Rosa and de la Casa, Miguel Angel and Alonso, Leyre and Nuñez, Mónica and Martí, Jaime and Arias, Fernando},
  title = {SBRT-SG-01: final results of a prospective multicenter study on stereotactic body radiotherapy for liver metastases},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03403-w}
}
Kostenlos starten →